Application Note: This content is compiled based on the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer (Version 1.2026), aiming to provide a popular science reference for doctor-patient communication. For specific medication use, please refer to the attending physician's treatment plan and the latest product labeling.
If an EGFR mutation is confirmed in non-small cell lung cancer, doctors usually recommend "osimertinib first." However, following the update of the 2026 NCCN Clinical Practice Guidelines for Non-Small Cell Lung Cancer, there are now more options available.
Overview of EGFR Mutations in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung cancers. The incidence rate of EGFR mutations in NSCLC is approximately 15%-20% in Western populations, while it reaches as high as 40%-50% in Asian populations.
The most common EGFR mutations are exon 19 deletion (19del) and exon 21 L858R point mutation, collectively known as "classic mutations" or "common sensitizing mutations," which yield the best response to targeted therapies.
Over the past decade, EGFR targeted drugs have continuously evolved, progressively extending the survival time of patients with EGFR-mutated NSCLC.
Three First-Line Regimens Formally Debuted
The 2026 NCCN Guidelines transition the previous paradigm, which was predominantly based on osimertinib monotherapy, into a new stage led by combination therapy.
Regimen 1: Osimertinib Monotherapy
The FLAURA study showed that first-line osimertinib yielded a median progression-free survival (PFS) of 18.9 months and a median overall survival (OS) of 38.6 months.
It has good blood-brain barrier penetration and relatively mild side effects. For patients with a good performance status who are reluctant to undergo chemotherapy, monotherapy remains a reliable choice.
Regimen 2: Osimertinib Combined with Platinum-Based Doublet Chemotherapy
This regimen is applicable only to non-squamous NSCLC and represents a major update in this version.
The FLAURA2 study (a global multicenter phase III trial involving 557 treatment-naive advanced NSCLC patients with EGFR mutations) demonstrated that the combination group had a median PFS of 25.5 months, superior to the 16.7 months of the monotherapy group (a 38% reduction in the risk of disease progression or death). The final OS analysis released in 2025 showed a median OS of 47.5 months for the combination group versus 37.6 months for the monotherapy group (a 23% reduction in the risk of death), with 3-year OS rates of 63% and 51%, respectively.
This is currently the only first-line combination regimen proven to provide a clear OS benefit in a phase III study. It is particularly suitable for patients with a high tumor burden who require rapid tumor shrinkage, though side effects such as myelosuppression need to be managed.
Regimen 3: Amivantamab Combined with Lazertinib
This employs a "dual-target" strategy (amivantamab blocks EGFR/MET, while lazertinib inhibits EGFR).
The MARIPOSA study (at a median follow-up of 22 months) showed a median PFS of 23.7 months for the combination group, superior to the 16.6 months for osimertinib monotherapy (a 30% reduction in risk). The final OS analysis presented at ELCC 2025 (at a median follow-up of 37.8 months) showed that the median OS for the combination group has not yet been reached, but it is extended by more than 1 year compared to the monotherapy group, with 3-year OS rates of 60% and 51%, respectively.
This regimen has shown positive intracranial response effects in patients with brain metastases. Vigilance is required for venous thromboembolism, skin adverse reactions, and infusion-related reactions.
How to Choose Among the Three Regimens?
All three are Category 1 recommendations. The specific choice should be personalized and decided by the attending physician by comprehensively considering tumor burden, performance status, brain metastasis status, comorbidities, and side effect tolerance.
Alternative Regimens
First- and second-generation TKIs (gefitinib, erlotinib—which can be combined with bevacizumab or ramucirumab—afatinib, and dacomitinib) as well as lazertinib monotherapy remain retained as "other recommendations." These regimens have thorough evidence-based support and lower costs, making them particularly suitable for patients who are diagnosed with EGFR mutations only during first-line chemotherapy and require a smooth transition to targeted therapy.
Easily Overlooked "Special Mutations"
EGFR exon 20 insertion (20ins): Accounts for 4%-12% of EGFR mutations and is virtually ineffective against traditional TKIs. The 2026 guidelines clearly designate first-line options to include amivantamab combined with carboplatin plus pemetrexed (the PAPILLON regimen); sunvozertinib (approved in China) is also an option, subject to domestic indications.
Uncommon mutations (G719X/S768I/L861Q): The guidelines recommend afatinib or osimertinib as preferred choices. The FDA has approved afatinib for metastatic NSCLC harboring L861Q, G719X, and S768I.
What to Do After Drug Resistance Develops
If resistance develops after first-line use of a first- or second-generation TKI and a repeat biopsy detects a T790M mutation, patients should switch to osimertinib.
If resistance develops after first-line osimertinib and T790M is not the primary mechanism, a repeat biopsy is required to identify resistance genes (such as MET amplification, C797S, etc.). Second-line choices recommended by the 2026 guidelines include: chemotherapy (with or without bevacizumab), Dato-DXd (suitable for non-squamous cancer without targeted resistance mechanisms), amivantamab combined with chemotherapy, or lazertinib combined with amivantamab, etc. Specific plans must be determined by the physician based on test results and performance status.
From "monotherapy targeting" to "precision combination," the biggest change brought to EGFR-mutated patients by the 2026 guidelines is the enrichment of "choices." Please communicate fully with your attending physician and select the most suitable path based on your personal condition.
Remember: Guidelines are for reference only, and treatment plans must strictly follow medical advice.
